CHICAGO -- Adding sotatercept (Winrevair) to the treatment regimen for pulmonary arterial hypertension (PAH) in high-risk ...

Tenaya Therapeutics, Inc.’s TNYA share price has dipped by 11.06%, which has investors questioning if this is right time to buy.

Verve Therapeutics, Inc.’s VERV share price has dipped by 11.69%, which has investors questioning if this is right time to buy.

Greater Than, a global provider of risk intelligence into road safety and climate impact, is announcing that Mia Alholm is proposed to be elected as a new Board member. Alholm has held the position of ...

The interim results of a phase 3 trial of Merck’s pulmonary arterial hypertension (PAH) treatment Winrevair were so ...

Serina Therapeutics Background Information (This description ... targeting human aging and degenerative diseases in the united states. the company's lead cell-based therapeutic candidates in ...

3 Reasons Investors Watch United Therapeutics (UTHR) Over the last six months, United Therapeutics shares have sunk to $308.27, producing a disappointing 14% loss - worse than the S&P 500’s 1.4% ...

In this article, we are going to take a look at where United Therapeutics Corporation (NASDAQ:UTHR) stands against other most profitable biotech stocks to buy right now. With improved market ...

United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that Great Place to Work® and Fortune magazine recognized the company as one of the Fortune 100 Best ...

United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The firm had revenue of $735.90 million for the quarter, compared to analyst estimates of $734.74 million.